▌在生物医药领域激烈角逐中,专利无疑是药企的核心竞争力与 “护城河”。日前,百济神州与Pharmacyclics LLC的专利侵权纠纷迎来大结局,百济神州在这场历时两年的专利战中全面胜诉,为中国药企出海提供了教科书式的应对策略。2025年10月8日,百济神州发布公告,艾伯维旗下Pharmacyclics公司自愿撤回对百悦泽®(泽布替尼)的侵权诉讼,案件已做出终局处理。本案始于2023年6月,...
Source Link▌在生物医药领域激烈角逐中,专利无疑是药企的核心竞争力与 “护城河”。日前,百济神州与Pharmacyclics LLC的专利侵权纠纷迎来大结局,百济神州在这场历时两年的专利战中全面胜诉,为中国药企出海提供了教科书式的应对策略。2025年10月8日,百济神州发布公告,艾伯维旗下Pharmacyclics公司自愿撤回对百悦泽®(泽布替尼)的侵权诉讼,案件已做出终局处理。本案始于2023年6月,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.